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Abbreviations
E.coli, Escherichia coli; FMDV, Foot and Mouth Disease 
Virus; HRP, horse radish peroxidase; IMAC, immobilised metal 
affinity chromatography; kDa, kilodaltons; P1, polyprotein 1; 
PBS, phosphate buffered saline; SDS-PAGE, sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis; Sf9, Spodoptera 
frugiperda cell line 9; SUMO, small ubiquitin-like modifier; 
VP0, virus protein 0; VP1, Virus protein 1; VP2, virus protein 2; 
VP3, virus protein 3; VP4, virus protein 4.
Introduction
Foot-and-mouth disease virus, FMDV, classified in the aphthovi-
rus genus of the Picornaviridae family, causes vesicular disease 
in a number of cloven-footed species, typically cattle, sheep and 
pigs1. In developed economies outbreaks of the disease in farmed 
herds are associated with significant financial loss while in less 
developed economies a loss of milk yield and fecundity have a 
direct community impact. Where possible the disease is con-
trolled by vaccination and slaughter2 but the virus evolves 
constantly to evade host immunity leading to multiple strains3. 
The antibodies raised during natural infection, or following 
vaccination, are restricted to predominant immunogenic regions 
on the virion surface and frequently have a very narrow spectrum 
of reactivity4,5. Antibodies to virus non structural proteins are 
more cross reactive (e.g. 6,7) but are of limited value for vaccine 
research programs which are necessarily focused on only the 
structural proteins. Some broad-ranging detection agents such 
as recombinant integrin, a soluble form of the virus receptor, 
have been developed8,9 but as alternate virus receptors have been 
described10 these may not react with all isolates.
We have developed systems for the expression of recom-
binant empty FMDV capsids, principally for use as potential 
vaccines11,12. Since these capsids contain no genome, PCR-based 
methods of quantitation13 are impossible and their characterisa-
tion relies extensively on antibody reactivity. However, strain 
divergence is such that antibodies suitable for the detection of a 
wide range of isolates can be difficult to source.
To generate an antibody reagent capable of detecting the 
majority of FMDV isolates we made use of the recent finding 
that fusion of the individual structural proteins of the virus, VP0, 
VP1 and VP3 to the small ubiquitin-related modifier (SUMO) 
protein as a carrier allows efficient expression and purifica-
tion of each mature protein in E.coli14,15. Of these, VP1 and VP3 
exhibit extensive serotype variation making them unsuitable 
as the basis of a universal serum reagent while much of VP0 is 
less variable. VP0 is an assembly intermediate protein that 
is incorporated into virus particles and then cleaved auto- 
catalytically into VP4+VP2 coincident with the incorporation of 
the RNA genome1. Part of the VP2 sequence lies on the surface 
of the virus particle and is subject to antigenic variation, similar 
to that observed for VP1 and VP3, but sections of VP2, and all of 
VP4, lie on the inside of the particle, are not under immune 
selection, and are highly conserved across serotypes. Thus, VP0 is 
a suitable candidate for the generation of a serum with potentially 
broad cross-reactivity.
Results and discussion
To produce VP0 protein, the sequence encoding VP0 from 
FMDV strains O1 Manisa Tur/69 one of the seven serotypes of 
FMDV worldwide, was fused in frame to the SUMO sequence 
in a T7 promoter driven bacterial expression vector (Figure 1A). 
Following transformation of an E.coli strain expressing the 
T7 polymerase, growth and induction, a SUMO-VP0 fusion 
protein with the predicted molecular mass of ~46kDa was iden-
tified in bacterial extracts (Figure 1B). Purification to homogene-
ity was achieved by virtue of the poly histidine tag present at the 
N-terminus of the SUMO domain and incubation with the 
SUMO specific protease Ulp116 produced two fragments 
representing the 11.5 kDa SUMO and ~33.5 kDa VP0 domains 
(Figure 1C). The free SUMO domain and any uncleaved 
SUMO-VP0 fusion protein were subsequently removed by adsorp-
tion to an IMAC resin and the resultant pure VP0 protein was 
used for immunisation.
A standard regimen of immunisation generated polyvalent sera 
in rabbits which were screened by western blot for reactivity 
with FMDV antigen expressed in insect cells11,12. In these tests, 
VP0 is produced in insect cells as part of the processing and 
assembly reaction of the P1 precursor protein (cf. Figure 1A) 
and the cleaved mature capsid proteins assemble into empty 
capsids, otherwise called virus like particles. As the genomic 
RNA is not present, VP0 does not generally undergo further 
cleavage to VP4 and VP2. Reactivity was apparent with a band 
of 37kDa consistent with the apparent molecular mass on 
SDS-PAGE of VP0 synthesised by a range of FMDV serotypes. 
Antibody reactivity in the serum generated reacted well with 
empty capsids representing serotypes A Iran 7/13, O1 Manisa, 
O Turkey 05/2009, Asia1 Shamir (Figure 2A) and SAT2 Zim 
7/83. To address if reactivity was also apparent on non-denatured 
antigen, the VP0 serum was also used as the primary antibody 
for flow cytometry of insect cells expressing each serotype 
following fixation and permeabilization. Reactivity was appar-
ent with all samples (Figure 2B) but the intensity of staining 
was somewhat lower than might be expected from the strength 
of reaction to denatured antigen. However, as relatively little 
of the VP0 sequence used to generate the sera is exposed on 
the surface of the virus particle, a lower reactivity to assembled 
capsids is plausible. Reactivity was also apparent with individual 
empty capsids when the serum was used for immunogold 
transmission electron microscopy (Figure 2C). Interestingly 
only some particles bound gold suggesting a subset with exposed 
epitopes. Finally, the VP0 serum was used to probe west-
ern blots of sucrose gradient purified virus from infected cell 
supernatants. These samples contain largely VP2, not VP0, as 
authentic virus has undergone VP0 maturation but neverthe-
less residual VP0 was detected for many of the samples tested, 
as was the more major cleavage product VP2 (Figure 2D). 
Despite reaction with whole virus the serum showed no 
neutralising activity (unpublished study, Eva Perez), consist-
ent with the principle neutralising determinants of FMDV 
being present in the VP1 protein1. To identify the linear epitopes 
underpinning the breadth of the observed reactivity, epitope 
mapping was done using peptide microarrays of both O1 
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Figure 1. Construction, expression and purification of FMDV VP0. A. Cartoon showing the location of VP0 in the structural protein precursor 
P1 and its relation to the other mature structural protein VP1, VP3, VP4 and VP2 as well as its configuration as a SUMO fusion protein 
B. Western blot, of bacterial expression cultures. Lanes 1 and 3, the SUMO vector alone, lanes 2 and 4, the SUMO-VP0 fusion protein. Lanes 
1 and 2 were blotted with a FMDV serum and lanes 3 and 4 were blotted with a His tag serum. C. Coomassie blue stained gel of VP0 proteins 
purified from bacteria, Lanes 5 and 6 purified SUMO-VP0 before and after digestion with SUMO protease. The various individual proteins are 
indicated.
Manisa sequence used for VP0 expression and, to include a more 
phylogenetically distant serotype, the SAT2 Zim VP0 
sequence. Multiple epitopes were apparent, but in the main they 
clustered in the amino-terminal VP4 region of the protein rep-
resenting only ~10% of the polypeptide used as immunogen 
(Figure 3A). Specifically, the major epitopes spanned residues 
8–18 near the amino terminus of VP4 and residues 28–40 further 
downstream. The major epitope in VP2 comprised residues 
5–14 at the amino terminus with more minor reactivity towards 
the carboxyl terminus (Figure 3B). In the three-dimensional 
structure of FMDV O1 Manisa17 the identified VP4 epitopes 
lie in a disordered region where no clear polypeptide chain 
mapping is possible (Figure 4). The predominant VP2 epitope is 
visualised but is distended away from the main body of the pro-
tein while the minor VP2 epitopes at residues 145–152 and 
200–207 lie within the main fold. The epitope mapping data 
would be consistent with poor antibody induction by the tightly 
folded β-sheet rich “jelly-roll” fold of the VP2 domain but ready 
antibody induction to the much less ordered and distended 
regions. A similar observation has been made for a related 
picorna-like virus, Israeli acute paralysis virus, following expres-
sion, immunisation and epitope mapping of the resulting serum18. 
The lack of epitopes in the classic fold of VP2 within the 
VP0 protein lends support to the suggestion that the unprocessed 
polyprotein in solution adopts a structure not dissimilar to that 
found in the native virus19,20.
Virus diversity in the natural environment, such as that shown 
by FMDV, provides the impetus for the development of novel 
control solutions, such as new candidate vaccines. But a corollary 
is often that the reagents available to characterise such novel 
products, for example those developed to newly emerged 
strains, are limited. Our data show that a focus on the most con-
served polypeptide sequence of the virus particle, coupled with 
efficient, non-denaturing purification of the requisite protein 
can provide an immunogen able of generating a serum that is 
cross reactive for many strains. Epitope mapping confirmed the 
basis of such cross reactivity was short conserved sequences 
predominantly at the N-terminus of VP4. The serum per-
formed well on denatured antigen whether it was VP0 (empty 
capsids) or VP2 (virus) but titres were reduced on assembled 
forms of the same proteins consistent with most epitopes 
being inside the particle. The low but very specific labelling 
of particles observed by TEM could therefore represent 
deformed particles which expose the inner surface or the tran-
sient exposure of internal epitopes on the intact particle surface, 
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Figure 2. Test of VP0 serum by western blot and flow cytometry. A. Detection of VP0 by western blot of insect cells expressing recombinant 
empty capsids. Lane 1 – A Iran 9/97, Lane 2 - O1 Manisa, Lane 3 – O Turkey 5/09, Lane 4 – SAT2 Zim 7/83, Lane 5 – Asia1 Shamir, Lane 6 
– control. B. Mean fluorescence of insect cells expressing the same serotypes as in panel A following staining by the VP0 serum and analysis 
by flow cytometry. C. Labelling of individual empty capsids by the VP0 serum and a gold conjugate. The empty capsids were of the A22 Iraq 
serotype and the field is typical of 6 micrograms recorded. Note only a subset of particles are labelled, some indicated. A lack of free gold 
particles suggests specific labelling even at high serum concentrations (1:50). The bar is 100nm. D. Detection of processed VP2 in native 
virus purified by sucrose gradient by western blot. The lane are 1 – O 1 Manisa, 2 – A 22 Iraq, 3 - Asia 1 Shamir, 4 – SAT2 Egypt. The cluster 
of bands around 25kDa on the stained gel (left panel) are the virus capsid proteins, including VP2, others are cellular contaminants. VP2 is 
identified by a VP2 monoclonal antibody (center panel) and by the VP0 serum (right panel). Markers to the left are in kilodaltons. Arrows to 
the right indicate VP0 (upper) and VP2 (lower).
originally observed for rhinovirus and termed “breathing”21. 
Interestingly, for picornavirus examples where the breathing 
intermediate has been captured structurally, it is residues 1–50 at 
the N terminus of VP4 that are exposed22,23, consistent with the 
predominant targets of the serum generated here. 
Conclusions
The picornaviridae contain many examples where strain vari-
ation among family members is extensive. Our data suggest that 
the same principle of serum generation by highly purified VP0 
could be used to generate a broadly reactive serum in these 
cases also.
Methods
Cloning and expression vector construction
The sequences encoding the VP0 section of the FMDV strains 
described were taken from the databases but synthesised 
de novo as dsDNA fragments (gBlocks - Integrated DNA Tech-
nologies, Leuven, Belgium). They were assembled into SUMO 
expression cassettes by ligation of a restriction fragment or 
by an infusion reaction such that fusion of the VP0 sequence 
was at the C-terminus of the SUMO domain. All vectors were 
sequence verified before use (Sanger sequencing service, Source 
Bioscience, Nottingham, UK). Expression generally used 
E.coli BL21 DE3 pLysS as described24,25. A number of FMDV 
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Figure 3. Epitope mapping of serum. A. Relative reactivity of the rabbit serum raised to the O1 Manisa VP0 on peptide arrays of O1 Manisa 
and SAT2 Zim. B. The major epitopes identified in the O1Manisa sequence shown as bold underlined text in the complete sequence. The 
junction of VP4 and VP2 is indicated by the green bar.
sequences were used in the characterisation of the serum, 
either as purified virus grown in BHK21 cells or virus-like-
particles expressed in insect cells including A Iran 9/97, A22 
Iraq, Asia 1 Shamir, O Turkey 05/2009, O 1 Manisa, SAT2 
Zim 7/83 and SAT2 4/2012 Egypt.
SDS-PAGE analysis
Samples of E.coli were resuspended directly in SDS loading 
buffer, boiled for 5 minutes, cooled, vortexed to shear bacte-
rial DNA and spun briefly to remove insoluble murein (3 min, 
13000 rpm bench microfuge). The equivalent of 50 microliters 
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of original culture per well was applied of a 10% precast 
SDS-PAGE gel (Cat. No. 4561033 BioRad, Carlsbad, USA). 
Electrophoresis used a Mini-PROTEAN Tetra Cell (Cat. 
No. 1658004 BioRad, Carlsbad, USA) and was performed 
at 190V constant voltage for 30 minutes. Samples of insect 
cell lysate or purified virus were mixed with SDS loading 
buffer and prepared similarly. Gels were either stained with 
Coomassie blue or used for western blot.
Western blot analysis
Gels were transferred to Immobilon filters (Immobilon P 
Cat. No. IPVH00010 EMD Millipore) by semi-dry electro 
transfer using a HorizeBLOT 4M-R (Cat. No. WSE-4040 ATTO 
Corporation, Tokyo, Japan) operating at 12V for 60 minutes 
and the membrane blocked using 5% dried milk powder in PBS 
for 1 hour at room temperature or 4°C overnight. Following 
blocking, membranes were rinsed and washed twice in PBS + 
0.5% Tween-20 (Sigma) (PBS-T). The primary rabbit antibody, 
produced as described herein, was diluted in PBS-T + 0.5% 
milk powder and incubated with the membrane for 1 hour at 
room temperature, followed by washing twice (15 minutes 
each) in PBS-T. A polyclonal anti-rabbit IgG conjugated to HRP 
(Cat. No. P0448, Agilent DAKO, Cheshire, UK) was diluted 
in PBS-T + 0.5% dried milk powder and incubated with the 
corresponding blot for 1 hour at room temperature. HRP detection 
used an ECL western blot detection reagent (EZ-Chemilumi-
nescence Cat. No. K1-0170 GeneFlow Ltd, Lichfield, UK) 
and the filter was imaged while luminescent on a Syngene 
Chemi XL imager.
Immunogold labelling
Empty FMDV capsids, purified as described11 were adsorbed to 
carbon coated formvar grids by floating the grid on a droplet of 
sample for 5 minutes at room temperature. The grid was washed 
briefly in water and floated sequentially on a 1:5 dilution of 
the VP0 serum followed by a 1:50 dilution of a polyclonal 
anti-rabbit antibody conjugated to 10nm gold (Cat. No. G7402 
Sigma-Aldrich, Poole, UK), each for 10 minutes at room 
temperature. The grids were washed with distilled water and 
counter stained with 2% uranyl acetate before examination using 
a Joel TEM operating a 200kV. 
Flow cytometry
Insect cells (Sf9) expressing VLPs of the serotypes shown were 
grown in suspension cultures at 27 °C with shaking at 110rpm 
in EX-CELL® 420 Serum-Free Medium (Cat. No. 14420C 
Sigma-Aldrich, Poole, UK), harvested at 3 days post infection 
and fixed and permeabilized with BD Cytofix/Cytoperm 
(BD Bioscience). They were incubated with rabbit anti-VP0 
serum (1:1000), washed and incubated with a polyclonal 
Figure 4. Location of the recognised epitopes in the FMDV structure. On the left the protomeric building block of the virus icosahedral 
shell comprising one copy each of VP4 (yellow), VP2 (green) VP3 (orange) and VP1 (blue) is shown in side profile. To the centre and right VP1 
and VP3 have been removed for clarity and the structure of VP4 and VP2 shown with a side or top profile with the identified epitopes coloured 
red. Where epitopes lie in an unstructured region they are indicated by a dashed red line which is for illustration only, the actual meander of 
the polypeptide in this region is unknown.
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anti-rabbit IgG conjugated to FITC (Cat. No. F9887 Sigma-
Aldrich, Poole, UK). Cells were analysed on a BD FACscan 
using CellQuest (Version 3.3 BD Bioscience) and the mean 
fluorescence intensity plotted. 
Serum generation
Serum generation was outsourced to Covalab Cambridge, UK. 
VP0 sera were raised in 2 New Zealand female rabbits follow-
ing a standard regimen of prime and two boosts with Freund’s 
complete and Freund’s incomplete adjuvant respectively 
(Standard Polyclonal Service Pack, 53 day protocol, Covalab 
Cambridge, UK). Each immunisation used 25 micrograms 
of purified VP0 protein and seroconversion was confirmed 
by western blot of a test bleed taken 2 weeks after the first 
boost. The VP0 serum has been registered with the Antibody 
Registry as Ian Jones; University of Reading, Cat# Anti-VP0 
Man, RRID: AB_2732804.
Microarray epitope mapping
The serum was subject to epitope mapping at single amino 
acid resolution on commercial peptide arrays of the VP0 
protein comprising 20mer peptides overlapping by 1 amino acid 
(PEPperMAP® Service, PEPperPRINT, Heidelberg, Germany).
Data availability
The VP0 serum described here has been registered with the 
Antibody Registry with the designation AB_2732804.
The data underlying this study is available from the Open 
Science Framework. Dataset 1: Wellcome Open Research 
https://doi.org/10.17605/OSF.IO/9CRN226
This dataset is available under a CC0 1.0 Universal license.
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